In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....

Ref: GLL/BSE/2026-/A2ug7 - Date: August 14, 2026 To To The General Manager, The Listing Manager, Corporate Relations Department, The Ahmedabad Stock Exchange Limited BSE Limited A-2, Kamdhenu Complex, Opp. Sahajanand Phiroze Jeejeebhoy Towers, College, 120 Feet Ring Road, Panjara Pol, Dalal Street, Mumbai - 400001. Ambawadi, Ahmedabad - 380015. Maharashtra State, India. Gujarat State, India. Script Code: 531739 Script Code: The Calcutta Stock Exchange Limited, #7, Lyons Range, Murgighata, Dalhousie, Kolkata - 700001, West Bengal State, India. Scrip Code: 26178 Dear Sir/Madam, Sub: Outcome of the Board Meeting of Gennex Laboratories Limited - Scrip Code: 531739/GENNEX Ref: Regulation 29, 33 & 47 of the SEBI (LODR) 'Regulations, 2015. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2026 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2026 (annexed here with}; 3. Other Business items. We hereby submit that the Board Meeting had commenced at 4:00 PM and concluded at 4.40 PM. This intimation is also uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. Thanking you, Yours faithfully For Gennex Laboratories Limited Dinesh Kumar Kejriwal Company Secretary & Compliance Officer Membership #A19293 Gennex Laboratories Limited Office: ‘Akash Ganga’ 4" Floor, Plot NO.144, Srinagar colony, Hyderabad-500073, T.S. India | Phone: +91-40-67334400 (30 Lines), Fax: +91-40-67334433 Factory: Sy.No.133, IDA Bollaram, Jinnaram Mandal, Sangareddy Dist — 502325, Telangana, India | Tel: +91-08458 279406, Telefax: +91-08454 279516 Info(@gennexlab.com, www.gennexlab.com i CIN :L24230TG1990PLC011168 GENNEX LABORATORIES LIMITED Registered Office : Sy.No.133, Bollaram, Jinnaram Mandal, Dist : Sangareddy, Telangana - 502 325. INDIA Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlak CIN : L24230TG1990PLC011168 Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2026 |(Rs. In Lacs) Standalone Consolidated SNo. [PARTICULARS Quarter ended Year ended Quarter ended Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) 1 Income Revenue from Operations 3,467.79 3,671.41 2,564.00 11,985.67 3,984.17 6,095.50 3,417.75 17,274.09 Other Income 199.70 129.79 226.44 814.01 200.82 131.87 227.74 824.58 Total Income 3,667.49 3,801.20 2,790.44 12,799.68 4,184.99 6,227.37 3,645.49 18,098.67 2 Expenses (a) Cost of material consumed 2,601.43 3,383.62 1,826.97 9,682.79 2,967.25 5,528.78 2,381.96 13,961.93 (b) Purchase of stock-in-trade - - - - - - - - (c) Changes in stock-in-trade and Work in 93.83 -252.90 -98.80 -929.37 -3.54 -266.66 -162.26 -1,109.46 Progress and stock in trade (d) Employees Cost 166.47 82.82 188.03 667.44 197.57 117.10 269.02 803.89 (e) Depreciation 23.92 34.94 19.87 246.69 56.89 107.66 50.40 419.82 (f) Finance Cost 50.88 63.11 59.15 96.76 89.97 116.05 97.90 264.80 (g) Other Expenses 310.43 139.28 310.26 1,151.67 385.21 127.69 421.82 1,373.92 Total Expenses 3,246.96 3,450.87 2,305.49 10,915.98 3,693.35 5,730.62 3,058.84 15,714.90 3 Total Profit before exceptional Items & 420.53 350.33 484.95 1,883.70 491.64 496.75 586.64 2,383.77 Tax. 4 Exceptional items - - - - - - - - Corporate Social Responsibilites - 30.00 - 60.00 - 30.00 - 60.00 5 Total profit before tax 420.53 320.33 484.95 1,823.70 491.64 466.75 586.64 2,323.77 6 Tax expense for earlier years - - - - - - - - 7 Curent tax 25.00 - 70.00 190.00 25.00 - 85.00 205.00 8 Deferred Tax - 20.89 - 20.89 - 20.89 - 20.89 9 Total Tax Expenses 25.00 20.89 70.00 210.89 25.00 20.89 85.00 225.89 10 Net profit (Loss) 395.53 299.44 414.95 1,612.81 466.64 445.86 501.64 2,097.88 11 Share of profit (loss) of associates and joint - - - : - - - - ventures accounted for using equity method 12 Total Profit (losss) for period 395.53 299.44 414.95 1,612.81 466.64 445.86 501.64 2,097.88 13 Other comprehensive income net of taxes - - - - - - - - 14 Total Comprehensive income for the period - 5.19 - 5.19 - 5.19 - 5.19 15 Total Comprehensive income for the 395.53 304.63 414.95 1,618.00 466.64 451.05 501.64 2,103.07 period attributable to Comprehensive income for the period - - - - 431.79 379.02 459.16 1,850.69 attributable to owners of parent Total comprehensive income for the period - - - - 34.85 72.03 42.48 252.38 attrributable to owners of parent non controlling interests 16 Details of equity share capital Paid up equity share capital 2,429.48 2,429.48 2,314.48 2,429.48 2,429.48 2,429.48 2,314.48 2,429.48 Face value of equity share capital in Rs 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 17 Earnings per share - Basic 0.163 0.125 0.179 0.666 0.192 0.156 0.217 0.762 - Diluted 0.163 0.125 0.171 0.666 0.192 0.156 0.206 0.762 Notes to the results: 1 The above unaudited financial results have been reviewed by the Audit Committee of its meeting held on 14.08.2026 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day. 2 The Statutory Auditors of the Company have carried out the Limited review of the above unaudited financial results for the Quarter ended June 30, 2026. 3 The above results have been prepared in accordance with the Companies (Indian Accounting Standards } Rules,2015 (IND-AS) prescribed u/s 133 of the Companies Act, 2013 and other recognished accounting practices and policies to the extent applicable. 4 The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Primary segment and believes that the Company has only one reportable segment namely "Bulk Drugs,Bioteck Products and Intermediates". Previous period's figures have been rearranged/regrouped wherever necessary. 5 Adjustment of actuarial valuation in respect of compliance with Accounting Standard- |AS-19-'Employee Benefits' is to be done at the year end. 6 Quarter ended 30th June,2026 Consolidated figures includes Sales (Net) of 271.93 lacs & Purchase(Net) of Rs 41.20 lacs to subsidiary "Deccan Remedies Ltd". 7 The quarterly unaudited financial results for the Quarter ended June 30, 2026 are available on the Company's Website i.e; www.gennexlab.com and also available on BSE website i.e; www.bseindia.com. For and on behalf of the Board For Gennex Laboratories Limited Digitally signed by ARI HANT ARIHANT BAID. Date: 2026.08.14 A BAID B id 168.28 +05'30' Place: Hyderabad rihan' al Date: 14.08.2026 Managing Director R Pugalia & Company Chartered Accountants 20 E Lake Road Kolkata-700029 Limited Review report on Unaudited Consolidated financial results for quarter ended 30" June, 2026 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015. The Board of Directors, M/s. Gennex Laboratories Limited, Hyderabad. 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of M/s. Gennex Laboratories Limited ("the Company") and its share oft he net profit/(loss) after tax and total comprehensive income / loss of its Subsidiary for the quarter ended June 30, 2026, and for the period from April 01, 2026 to June 30, 2026 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended June 30, 2026 as reported in these financial results have been approved by the Company's Board of Directors, but h [Showing first 8,000 characters — download PDF for full document]